{
    "clinical_study": {
        "@rank": "18375", 
        "arm_group": [
            {
                "arm_group_label": "Statin", 
                "arm_group_type": "Active Comparator", 
                "description": "statin therapy (atorvastatin 20 mg/d) for 6 months"
            }, 
            {
                "arm_group_label": "usual care", 
                "arm_group_type": "No Intervention", 
                "description": "follow up group with no intervention"
            }, 
            {
                "arm_group_label": "lifestyle counseling", 
                "arm_group_type": "Active Comparator", 
                "description": "lifestyle modification by dietician counseling and follow-up"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the current study is to evaluate the association of fatty liver severity and\n      endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients and to find the\n      impact of statin treatment compared to usual care or life style modification on endothelial\n      function, liver steatosis and fibrosis."
        }, 
        "brief_title": "Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Alcoholic Fatty Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study cohort will include 150 patients with fatty liver per ultrasound or histology. The\n      patients will be divided randomly to one of three arms: follow up group, lifestyle\n      modification group, and statins therapy (Atorvastatin 20mg/d for 6 months). at screening,\n      after 6 months (end of treatment), and 12 months the patients will undergo:\n\n        1. complete physical examination\n\n        2. blood pressure measurement\n\n        3. assessment of height and weight, body mass index and waist circumference\n\n        4. blood samples for complete blood count, fasting plasma glucose, fasting plasma insulin,\n           lipid profile, liver enzymes, albumin, bilirubin, Prothrombin time (PT INR), Hemoglobin\n           A1c, ferritin, adiponectin, C-reactive protein, Tumor necrosis factor alpha,\n           Lipoprotein-phospholipase A2, Apolipoproteins B100, A1, C3, C4, ceruloplasmin\n\n        5. Liver elastography and sonographic liver fat quantification\n\n        6. Brachial artery flow-mediated dilatation (FMD) measurement"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects willing to comply with study requirements and have signed an informed\n             consent form\n\n          -  fatty liver per abdominal ultrasound or liver biopsy\n\n        Exclusion Criteria:\n\n          -  alcohol drinking >140g/week\n\n          -  presence of hepatitis B or C or HIV\n\n          -  known liver disease other than fatty liver\n\n          -  usage of drugs known to cause liver steatosis\n\n          -  subjects with known allergies or hypersensitivity to statins\n\n          -  subjects with known cardiovascular/cerebrovascular disease\n\n          -  subjects with known dyslipidemia requiring drug treatment\n\n          -  subjects with diabetes mellitus\n\n          -  history of drug or alcohol abuse\n\n          -  refusal to sig the informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987310", 
            "org_study_id": "SHEBA-13-0694-ZBE-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Statin", 
                "description": "atorvastatin 20 mg per day for 6 months", 
                "intervention_name": "atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Atorvastatin Teva, Lipitor, Litorva"
            }, 
            {
                "arm_group_label": "lifestyle counseling", 
                "description": "lifestyle modification by dietician counseling and follow up", 
                "intervention_name": "lifestyle counseling", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non alcoholic fatty liver disease", 
            "endothelial function", 
            "liver steatosis", 
            "liver fibrosis", 
            "statin treatment"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "last_name": "Ziv Ben-Ari, MD", 
                "phone": "972-3-5307180"
            }, 
            "contact_backup": {
                "last_name": "Oranit Cohen-Ezra, MD", 
                "phone": "972-3-5307181"
            }, 
            "facility": {
                "address": {
                    "city": "Ramat Gan", 
                    "country": "Israel", 
                    "zip": "5265601"
                }, 
                "name": "Sheba Medical Center"
            }, 
            "investigator": {
                "last_name": "Ziv Ben-Ari, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment", 
        "overall_official": {
            "affiliation": "Sheba Medical Center, Ramat Gan, Israel", 
            "last_name": "Ziv Ben-Ari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on liver steatosis and fibrosis. Liver steatosis will be assessed by sonographic liver fat quantification (hepatorenal sonographic index.", 
                "measure": "Change from baseline in liver steatosis at 6 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 months and 12 months"
            }, 
            {
                "description": "Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on liver  fibrosis. Liver fibrosis will be assessed by Real-Time shear wave elastography.", 
                "measure": "change from baseline in liver fibrosis at 6 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 months and 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987310"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Prof. Ziv Ben-Ari MD", 
            "investigator_title": "Head of Disease Medical Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "measurement of endothelial function in NAFLD patients and finding the correlation between the degree of endothelial dysfunction and the severity of fatty liver disease. Endothelial function will be assessed by brachial artery flow-mediated (FMD) measurement at diagnosis and after 6 and 12 months. The severity of fatty liver disease will be assessed by liver elastography and sonographic liver fat quantification", 
                "measure": "endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "levels of liver enzymes, liver synthetic function, blood lipids, insulin resistance, ferritin, adiponectin, C reactive protein, Tumor necrosis factor alpha and ceruloplasmin and their correlation with liver steatosis and fibrosis", 
                "measure": "relationship between blood parameters and liver steatosis and fibrosis", 
                "safety_issue": "No", 
                "time_frame": "12  months"
            }, 
            {
                "description": "levels of liver enzymes, liver synthetic function, blood lipids, insulin resistance, ferritin, adiponectin, C reactive protein, tumor necrosis factor alpha and ceruloplasmin and their correlation with endothelial function", 
                "measure": "relationship between blood parameters and endothelial function", 
                "safety_issue": "No", 
                "time_frame": "at diagnosis and after 6 months and 12 months"
            }, 
            {
                "description": "Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on endothelial function. Endothelial function will be assessed by flow mediated dilatation (FMD) of brachial artery.", 
                "measure": "change from baseline in endothelial function at 6 months", 
                "safety_issue": "No", 
                "time_frame": "at diagnosis 6 months and 12 months"
            }
        ], 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}